Premium
Chronic myeloid leukemia with an e13a3 BCR‐ABL fusion: Benign course responsive to imatinib with an RT‐PCR advisory
Author(s) -
Snyder David S.,
McMahon Ross,
Cohen Sandra R.,
Slovak Marilyn L.
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.10456
Subject(s) - imatinib , myeloid leukemia , medicine , breakpoint cluster region , fusion gene , abl , cancer research , leukemia , oncology , tyrosine kinase , biology , gene , receptor , genetics
Abstract A case of a patient with chronic myeloid leukemia whose cells expressed an e13a3 (b2a3) variant BCR‐ABL p210 mRNA is presented. The variant splice was detected by a qualitative reverse transcriptase polymerase chain reaction using primers complementary to BCR exon 13 (b2) and ABL exon 3 (a3). The patient responded well to imatinib and achieved a complete cytogenetic response. Am. J. Hematol. 75:92–95, 2004. © 2004 Wiley‐Liss, Inc.